Last reviewed · How we verify
NCT05912686
High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients
Phase 4 trial testing Atorvastatin 80mg in Mechanical Thrombectomy in 162 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Zhongda Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 162 |
| Start date | 1 July 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 31 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Atorvastatin 80mg — full drug profile →
- Atorvastatin 20mg — full drug profile →
Conditions studied
- Mechanical Thrombectomy — all drugs for Mechanical Thrombectomy →
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Zhongda Hospital
Who can join
Adults 18 to 80, any sex, with Mechanical Thrombectomy or Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project investigates the impact of statins on cerebral vascular wall damage after mechanical thrombectomy. The investigators will undertake a multi-center, prospective, parallel-controlled, open-label, superiority randomized controlled study based on past research on intense lipid-lowering intervention trials. Patients undergoing post-thrombectomy will be divided into two groups: the test group and the control group. After surgery, the test group will be given a high dose of atorvastatin (80mg/day), followed by a standard dose (20mg/day). The control group will continue to receive the standard dose of atorvastatin (20mg/day). The investigators will compare the high-resolution vascular wall MRI characteristics (vascular wall enhancement, lumen stenosis rate, and so on) within 3-5 days of the operation, as well as the composite incidence of ischemic stroke, transient ischemic attack, intracranial hemorrhage 1 month postoperatively, and the modified Rankin Score at 90 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05912686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atorvastatin 80mg
Trials testing the same drug.
- NCT06841536 — Combined Effects of Statins and Exercise on Training Sensitive Health Markers · NA · completed
- NCT06871358 — The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients · NA · completed
- NCT06139952 — Ameliorating Contrast Induced Nephropathy After Coronary Angiography · Phase 4 · completed
- NCT05792540 — Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Dis · Phase 2 · completed
- NCT05567068 — Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis · Phase 2 · completed
Other recruiting trials for Mechanical Thrombectomy
Currently open trials in the same condition.
- NCT05561088 — Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke · NA · recruiting
- NCT04664933 — Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET) · NA · recruiting
Other Zhongda Hospital trials
Trials by the same sponsor.
- NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
- NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
- NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
- NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05912686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
- Last refreshed: 23 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05912686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing